Literature DB >> 2910429

Pyrimidine nucleotide synthesis is more extensive in poorly differentiated than in well-differentiated human gastric carcinoma.

Y Maehara1, T Kusumoto, Y Sakaguchi, H Kusumoto, Y Kido, H Anai, K Sugimachi.   

Abstract

In tissues obtained from patients undergoing gastrectomy, the activities of 12 enzymes involved in pyrimidine nucleotide synthesis: cytidine triphosphate (CTP) synthetase, deoxycytidine monophosphate (dCMP) deaminase, thymidine monophosphate (dTMP) kinase, uridine (Urd), deoxycytidine (dCyd) and thymidine (dThd) kinases, Urd, deoxyuridine (dUrd) and dThd phosphorylases, cytidine (Cyd) and dCyd deaminases, and DNA polymerase were examined in the eight-well-differentiated and 12 poorly differentiated gastric cancer tissues and the ten normal tissues. These cases were clinically advanced and serosal invasions were evident. Activities of these enzymes were higher in the poorly differentiated tissues than the well differentiated type and in the normal tissues. Significant differences were noted between the poorly differentiated and well-differentiated types, in dTMP kinase (P less than 0.02), dThd kinase (P less than 0.05), dThd phosphorylase (P less than 0.01), and DNA polymerase (P less than 0.05). The authors' findings show that the level of pyrimidine nucleotide synthesis, in both de novo and salvage pathways, is higher in the poorly differentiated gastric cancer tissues than in the well-differentiated type and suggest that antitumor drugs have an increased susceptibility in cases of poorly differentiated gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910429     DOI: 10.1002/1097-0142(19890101)63:1<96::aid-cncr2820630116>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer.

Authors:  Y Maehara; S Inutsuka; H Takeuchi; H Baba; H Kusumoto; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.

Authors:  Y Shimamoto; A Fujioka; H Kazuno; Y Murakami; H Ohshimo; T Kato; A Matsuda; T Sasaki; M Fukushima
Journal:  Jpn J Cancer Res       Date:  2001-03

3.  Comprehensive Multi-Omics Analysis Reveals Aberrant Metabolism of Epstein-Barr-Virus-Associated Gastric Carcinoma.

Authors:  Sang Jun Yoon; Jun Yeob Kim; Nguyen Phuoc Long; Jung Eun Min; Hyung Min Kim; Jae Hee Yoon; Nguyen Hoang Anh; Myung Chan Park; Sung Won Kwon; Suk Kyeong Lee
Journal:  Cells       Date:  2019-10-08       Impact factor: 6.600

4.  Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2.

Authors:  Yuji Shimamoto; Katsuhisa Koizumi; Hiroyuki Okabe; Hiromi Kazuno; Yuko Murakami; Fumio Nakagawa; Akira Matsuda; Takuma Sasaki; Masakazu Fukushima
Journal:  Jpn J Cancer Res       Date:  2002-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.